ID: ALA358017

Max Phase: Preclinical

Molecular Formula: C13H16N4O2

Molecular Weight: 260.30

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCn1cnc(C(Cc2ccc(N)nc2)C(=O)O)c1

Standard InChI:  InChI=1S/C13H16N4O2/c1-2-17-7-11(16-8-17)10(13(18)19)5-9-3-4-12(14)15-6-9/h3-4,6-8,10H,2,5H2,1H3,(H2,14,15)(H,18,19)

Standard InChI Key:  HWISMQLAUIIGRF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 260.30

Molecular Weight (Monoisotopic): 260.1273

AlogP: 1.29

#Rotatable Bonds: 5

Polar Surface Area: 94.03

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.65

CX Basic pKa: 7.65

CX LogP: -0.69

CX LogD: -0.77

Aromatic Rings: 2

Heavy Atoms: 19

QED Weighted: 0.84

Np Likeness Score: -0.02

References

1. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C, Cook JJ, Sitko G, Tiller PR, Miller-Stein CM, Rose M, McMasters DR, Vacca JP, Selnick HG..  (2003)  Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.,  46  (25): [PMID:14640538] [10.1021/jm034141y]

Source

Source(1):

• Scientific Literature